NCT01901653 - Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 28, 2016

Study Completion Date

November 28, 2016

Conditions

Recurrent Small Cell Lung Cancer

Interventions

DRUG

Rovalpituzumab tesirine (SC16LD6.5)

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Blue Ridge Cancer Care, Roanoke

Duke University Medical Center, Durham

Florida Cancer Specialists, Sarasota

University of Alabama at Birmingham, Birmingham

Tennessee Oncology, Nashville

University of Chicago Medical Center, Chicago

University of Texas MD Anderson Cancer Center, Houston